From: Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer
KPNA2 expression | |||||
---|---|---|---|---|---|
n | Negative | Weak | Positive | p-value | |
Age (years) | 0.746 | ||||
< 65 | 78 | 22 (28.2) | 36 (46.2) | 20(25.6) | |
≥ 65 | 117 | 37 (31.6) | 47 (40.2) | 33 (28.2) | |
Sex | 0.665 | ||||
Male | 83 | 25 (30.1) | 33 (39.8) | 25 (30.1) | |
Female | 112 | 34 (30.4) | 50 (44.6) | 28 (25.0) | |
Location | 0.664 | ||||
Right | 82 | 21(25.6) | 37 (45.1) | 24 (29.3) | |
Transverse | 18 | 9 (50.0) | 7 (38.9) | 2 (11.1) | |
Descendent | 18 | 5 (27.8) | 7(38.9) | 6 (33.3) | |
Left | 77 | 25(32.5) | 32 (41.6) | 20 (26.0) | |
AJCC stage | 0.01* | ||||
I | 22 | 12 (54.5) | 7 (31.8) | 3 (13.6) | |
II | 79 | 25 (31.6) | 37 (46.8) | 17 (21.5) | |
III | 76 | 21 (27.6) | 30 (39.5) | 25 (32.9) | |
IV | 18 | 1 (5.6) | 8 (44.4) | 9 (50.0) | |
N stage | 0.025* | ||||
N0 | 104 | 40 (38.5) | 45 (43.3) | 19 (18.3) | |
N1 | 57 | 14 (24.6) | 22 (38.6) | 21 (36.8) | |
N2 | 34 | 6 (17.6) | 15 (44.1) | 13 (38.2) | |
M stage | 0.014* | ||||
M0 | 177 | 58 (32.8) | 75 (42.4) | 44 (24.9) | |
M1 | 18 | 1 (5.6) | 8 (44.4) | 9 (50.0) | |
T stage | 0.018* | ||||
T1 + T2 | 28 | 14 (50.0) | 12 (42.9) | 2 (7.1) | |
T3 + T4 | 167 | 46 (27.5) | 71 (42.5) | 50 (30.0) | |
Differentiation | 0.001* | ||||
High | 97 | 39 (40.2) | 41 (42.3) | 17 (17.5) | |
Moderate | 68 | 13 (19.1) | 33 (48.5) | 22 (32.4) | |
Low | 30 | 8 (26.7) | 8 (26.7) | 14 (46.7) | |
Vascular invasion | 0.604 | ||||
Yes | 14 | 3 (21.4) | 8 (57.1) | 3 (21.4) | |
No | 181 | 56 (30.9) | 75 (41.4) | 50 (27.6) | |
Ki-67 expression | 0.002* | ||||
Negative | 36 | 11 (30.6) | 22 (61.1) | 3 (8.3) | |
Positive | 159 | 48 (30.2) | 60 (37.8) | 50 (31.4) |